Metraipolis › archive › dc_e84a2a08536d

Toxoplasma gondii as a drug for anti-tumor immunotherapy: mechanisms, challenges, and perspectives — Europe PMC PMID:41641877

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41641877
DOI
10.1051/parasite/2026006
License (as archived)
solo-consultazione
Archived
2026-11-06T02:13:32.879Z
SHA-256 of the archived text
142d4643e28aa8758113bc5f15baeb227d3d2d1a78ebd330e498911e7ca9ef6f
Stable URL of this page
https://metraipolis.com/documento/dc_e84a2a08536d

How to cite

Toxoplasma gondii as a drug for anti-tumor immunotherapy: mechanisms, challenges, and perspectives — Europe PMC PMID:41641877 — Europe PMC (en), https://europepmc.org/article/MED/41641877 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e84a2a08536d (Metraipolis archive dc_e84a2a08536d, sha256 142d4643e28aa8758113bc5f15baeb227d3d2d1a78ebd330e498911e7ca9ef6f)
BibTeX
@misc{dce84a2a08536d,
  title = {Toxoplasma gondii as a drug for anti-tumor immunotherapy: mechanisms, challenges, and perspectives — Europe PMC PMID:41641877},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41641877},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e84a2a08536d; sha256 142d4643e28aa8758113bc5f15baeb227d3d2d1a78ebd330e498911e7ca9ef6f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41641877. Agents can read the archived copy with the MCP tool read_document.